8-K: Cabaletta Bio Reports Strong Clinical Data for Rese-cel

Cabaletta Bio announced positive clinical data and development updates for its rese-cel therapy across multiple autoimmune disease trials, reinforcing its potential for durable, drug-free responses.

Summary

• Cabaletta Bio presented new clinical data and development updates for rese-cel (resecabtagene autoleucel) across RESET-Myositis, RESET-SSc, and RESET-SLE trials at ACR Convergence 2025.
• In the RESET-Myositis trial, all 4 dermatomyositis (DM)/antisynthetase syndrome (ASyS) patients meeting registrational criteria achieved immunomodulatory-free total improvement score (TIS) responses of moderate or major improvement at week 16.
• A DM/ASyS registrational cohort, expected to enroll 14 patients with a 16-week primary endpoint, is initiating this quarter, consistent with FDA alignment.
• Two of 4 immune-necrotizing myopathy (IMNM) patients with sufficient follow-up achieved immunomodulatory-free TIS responses at week 24.
• Preliminary Phase 1/2 data from 6 RESET-SSc patients showed all 4 patients with at least 3 months of follow-up achieved an rCRISS-25 response off immunomodulators and steroids.
• Preliminary Phase 1/2 data from 9 RESET-SLE patients indicated 3 of 4 SLE patients achieved DORIS, and the fourth achieved a complete renal response; 3 of 4 lupus nephritis (LN) patients showed renal response, all off immunomodulators.
• Patients in RESET-SLE achieved a median 8-point reduction in SLEDAI-2K and a significant reduction in anti-dsDNA antibodies.
• Safety across trials showed low-grade cytokine release syndrome (CRS) in most cases (e.g., 4 of 13 in Myositis, 3 of 6 in SSc, 3 of 9 in SLE) and rare immune effector cell-associated neurotoxicity syndrome (ICANS) events (one Grade 3 in SSc, one Grade 4 in SLE, both previously reported).
• Cabaletta is expanding a no preconditioning strategy into the RESET-SLE trial, with initial clinical data anticipated in 2026, based on promising early data from 3 RESET-PV patients.
• As of October 24, 2025, 76 patients were enrolled across 77 clinical trial sites globally.

Sentiment

Score: 8

Explanation: The filing presents compelling positive clinical data across multiple indications for rese-cel, demonstrating high response rates and a generally favorable safety profile. Key highlights include FDA alignment for a registrational trial in myositis, with enrollment initiating this quarter, and the expansion of a no-preconditioning strategy for lupus, which could significantly enhance patient accessibility and market differentiation. The consistent efficacy and safety data, coupled with a clear path to BLA submission for myositis by 2027, suggest strong potential for future commercialization and significant value creation. The unmet medical need in these autoimmune diseases further underscores the market opportunity.

Positives

• All 4 DM/ASyS patients meeting registrational criteria achieved the primary endpoint of moderate or major TIS responses at week 16, off immunomodulators.
• FDA alignment has been achieved for the DM/ASyS registrational cohort design, allowing for initiation this quarter.
• All 4 systemic sclerosis (SSc) patients with at least 3 months of follow-up achieved an rCRISS-25 response off all immunomodulators and steroids.
• Seven of 8 lupus (SLE) patients with at least 3 months of follow-up achieved DORIS or renal response, with all 9 patients off immunomodulators.
• The company is expanding a no preconditioning strategy into the RESET-SLE trial, potentially offering a simpler and more patient-focused alternative, especially for women of child-bearing potential.
• The overall safety profile supports potential outpatient administration, with 94% of 32 patients with preconditioning experiencing no CRS or only Grade 1 CRS, and 94% experiencing no ICANS.
• Myositis BLA submission remains on track for 2027, indicating a clear regulatory pathway.

Negatives

• A subset of ASyS and IMNM patients showed complete B cell elimination but did not lead to antibody clearance, suggesting CD19-negative long-lived plasma cells may be a source for pathogenic autoantibodies.
• One Grade 3 ICANS event was observed in RESET-SSc (previously reported in March 2025) and one Grade 4 ICANS event in RESET-SLE (previously reported in August 2024).
• Additional patients will be enrolled in the Phase 1/2 IMNM cohort with refined entry criteria prior to potential initiation of a registrational IMNM cohort, indicating further development is needed for this subtype.

Risks

• Risks related to regulatory filings and potential clearance.
• The risk that signs of biologic activity or persistence may not inform long-term results.
• Cabaletta's ability to demonstrate sufficient evidence of safety, efficacy, and tolerability in its preclinical studies and clinical trials of rese-cel.
• The risk that results observed with similarly-designed constructs or from one program may not translate to results for another program.
• Risks that modifications to trial design or approach may not have the intended benefits and that the trial design may need to be further modified.
• Risks related to clinical trial site activation, delays in enrollment generally, or enrollment rates that are lower than expected.
• Delays related to assessment of clinical trial results.
• Risks related to unexpected safety or efficacy data observed during clinical studies.
• Risks related to volatile market and economic conditions and public health crises.
• Cabaletta's ability to retain and recognize the intended incentives conferred by Orphan Drug Designation and Fast Track Designation or other designations.
• Risks related to Cabaletta's ability to protect and maintain its intellectual property position.
• Risks related to fostering and maintaining successful relationships with collaboration and manufacturing partners.
• Uncertainties related to the initiation and conduct of studies and other development requirements for its product candidates.
• The risk that any one or more of Cabaletta's product candidates will not be successfully developed and/or commercialized.
• The risk that the initial or interim results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies.

Future Outlook

Cabaletta Bio expects to initiate enrollment in the registrational DM/ASyS cohort this quarter, with a 16-week primary endpoint. The company anticipates FDA alignment on registrational cohort designs for systemic sclerosis and SLE/LN this year, and for generalized myasthenia gravis in the first half of 2026. A new dose-escalation cohort incorporating a no preconditioning strategy will be added to the RESET-SLE trial, with initial clinical data expected in 2026. The Biologics License Application (BLA) submission for myositis is projected for 2027, as the company aims to launch the first curative targeted cell therapy for autoimmune diseases.

Management Comments

• David J. Chang, M.D., Chief Medical Officer, stated that the clinical data reinforces the potential of a single weight-based dose of rese-cel to deliver durable, drug-free clinical responses across multiple autoimmune diseases, highlighting the encouraging consistency of responses through the primary endpoint in patients meeting key registrational inclusion criteria.
• Dr. Chang also noted the acceleration of plans to initiate a no preconditioning dose-escalation cohort in the RESET-SLE trial, believing this innovation can provide a simpler and more patient-focused alternative for lupus patients, many of whom are women of child-bearing potential.

Industry Context

Cabaletta Bio's progress with rese-cel positions it at the forefront of developing targeted cell therapies for autoimmune diseases, an area with significant unmet medical needs. Current treatments for conditions like myositis, systemic lupus erythematosus, and systemic sclerosis often involve chronic immunosuppression with substantial side effects and may not halt disease progression. Rese-cel, as an autologous CAR T cell therapy, offers a novel approach aiming for a 'one-and-done' curative treatment by resetting the immune system. The expansion of a 'no preconditioning' strategy, particularly for lupus patients, addresses a critical patient-centric need by potentially reducing treatment burden and risks associated with lymphodepleting regimens, which could significantly differentiate rese-cel in the competitive landscape of emerging autoimmune therapies.

Comparison to Industry Standards

• For dermatomyositis (DM), intravenous immunoglobulin (IVIg) is currently the only FDA-approved treatment option, while rese-cel aims to provide a durable, drug-free response.
• For antisynthetase syndrome (ASyS), there are currently no FDA-approved treatment options, highlighting rese-cel's potential to fill a significant therapeutic gap.
• In systemic sclerosis (SSc), autologous hematopoietic stem cell transplantation (AHSCT) is noted as the only treatment capable of halting pathology, but it carries high risks; rese-cel aims to offer a safer, transformative option.
• The B cell depletion observed with rese-cel is consistent with academic studies showing CD19-CAR T cell therapy achieves deeper depletion than monoclonal antibodies (mAbs).
• The safety profile of rese-cel with preconditioning (94% no CRS or Grade 1 CRS, 94% no ICANS) supports potential outpatient administration, which would be a significant advantage over traditional CAR T therapies that often require inpatient stays.

Stakeholder Impact

• Shareholders are likely to experience a positive impact due to strong clinical data, accelerated regulatory pathways for key indications, and the expansion of the pipeline, which could lead to increased company valuation.
• Patients suffering from severe autoimmune diseases such as myositis, systemic lupus erythematosus, and systemic sclerosis stand to benefit significantly from a potential durable, drug-free treatment option, especially with the development of a simpler, no-preconditioning regimen.
• Employees will likely experience positive morale and stability due to successful clinical development and a clear strategic direction towards commercialization.
• Regulatory bodies, particularly the FDA, will continue to be engaged in discussions regarding registrational pathways and trial designs, reflecting ongoing collaboration in bringing novel therapies to market.

Next Steps

• Initiate enrollment in the registrational DM/ASyS cohort within the RESET-Myositis trial this quarter (4Q25).
• Enroll additional patients in the Phase 1/2 IMNM cohort with refined entry criteria and follow existing patients to further evaluate efficacy and durability prior to potential registrational initiation.
• Anticipate FDA alignment on registrational cohort designs for systemic sclerosis and SLE/LN this year (2025).
• Anticipate FDA alignment on registrational cohort design for generalized myasthenia gravis (gMG) in 1H26.
• Incorporate a new dose-escalation cohort into the RESET-SLE trial with a no preconditioning strategy, with initial clinical data anticipated in 2026.
• Continue to present clinical data and development updates at scientific meetings.
• Advance the whole blood manufacturing program to eliminate apheresis.
• Execute commercial supply readiness and innovation, including the lentiviral vector (LVV) process at Oxford and drug product process at Lonza, with process qualification and validation activities planned for BLA submission.

Key Dates

Recommendation

The filing presents highly compelling positive clinical data across multiple indications for rese-cel, demonstrating robust efficacy with a generally favorable safety profile. The FDA's alignment on a registrational trial design for myositis, with enrollment commencing this quarter, significantly de-risks this program and accelerates its path to market. The expansion of a no-preconditioning strategy for lupus is a strategic move that could broaden patient access and enhance market differentiation. The consistent positive outcomes, coupled with a clear regulatory strategy and a projected BLA submission for myositis by 2027, indicate strong potential for future commercial success and substantial value creation. The high unmet medical need in these autoimmune diseases further amplifies the market opportunity for a potentially curative, drug-free therapy.

Keywords

Cabaletta Bio, rese-cel, CAR T cell therapy, Autoimmune diseases, Myositis, Dermatomyositis, Antisynthetase syndrome, Systemic lupus erythematosus, Lupus nephritis, Systemic sclerosis, Clinical trials, FDA alignment, Biotechnology, Immunology, Rheumatology